Hepatitis C infection is important global health problem with wide spectrum of health, social and economic consequences. Th e goal of this research was to estimate prevalence of hepatitis C virus infection in risk groups, and to determine association hepatitis C virus (HCV) infection and risk factors. Research included  subjects divided in two groups. Test group included  subjects divided in  subgroups with risk for HCV infection: those who received blood transfusion without screening on HCV (it was introduced in ) (); intravenous drug users (); patients on hemodialysis () and health care workers (). Control group included  healthy volunteer blood donors. In all subjects anti-HCV antibodies were tested with third generation ELISA test. Positive serum samples were tested for presence of HCVRNA, using reaction of reverse transcription and polymerase chain reaction. In all anti-HCV positive subjects further epidemiological and clinical workup was performed. Prevalence of HCV infection in risk groups was: , in subjects who have received blood transfusions without HCV blood screening,  in intravenous drug users, , in patients on chronic dialysis, and . in health care workers. In control group prevalence was low (,). In the group of  anti-HCV positive subjects, , had HCVRNA. Th e largest number of subjects with HCV infection was in the age group of - years (,). Th is study showed that multiple blood transfusions before introducing the blood screening for HCV, longer duration of intravenous drug abuse, longer duration of hemodialysis treatment, larger number of accidental injuries in health care workers are independent and statistically signifi cant risk factors for those groups examined. Results of this study confi rm that general screening for HCV infection is recommended in risk groups for HCV infection in order to identify to prevent and to treat it.
Introduction
Hepatitis C viral infection is signifi cant global health problem with a wide-ranging personal, social and economic impact. Globally, an estimated  million people, approximately  of the world's population, are infected with the hepatitis C () . Prevalence of hepatitis C viral infection ranges from , to more than  depending on the country (,,) . According to the data from B&H conference for consensus about hepatitis C, it is estimated that HCV prevalence infection is . and it is one of the most common blood transferred infection in B&H () . Th is estimation does not include the data about HCV infection in high-risk groups. Also, there is no valid data about the infl uence of war on high-risk groups HCV infection. In the area where this research was conducted, the war lasted from  to . During this period a large number of persons were wounded, and received blood and blood derivates in the course the treatment. In that period, up to the end of the year , testing of blood donors for HCV was not performed. Th erefore, it can be reasonably assumed that certain percentage of wounded who received blood at that time, were infected with HCV. Th e hepatitis C virus is primarily spread by direct contact by human blood. Routes of transmission vary between countries, and sources of infection include intravenous drug use, needle-stick accidents, and transfusions of blood or blood products (,) . Just about  of infected persons are actually diagnosed having HCV infection, so that majority of patients are still to be identifi ed. In the next ten years we expect the number of chronically infected HCV patients to triple, which obliges us to introduce proper means of diagnosis, prevention (including high-risk groups screening) and treatment () . Th e aim of this research was to determine prevalence of HCV infection in the risk groups (recipients of the possibly infected transfusions, intravenous drug users, hemodyalised patients and health -care workers) as well as the association of HCV infection with risk-factors.
Subjects and Methods
From  to  we did prospective study at the Clinic for infectious diseases, Policlinic for diagnostics; Psychiatry Clinic and Internal Clinic of the University Clinical Center Tuzla. Research was approved by the ethics committee of the University Clinical Center Tuzla. In this research we examined  subjects and they were divided into  groups: a) subjects with risk factors (), they subdivided into  high-risk subgroups for HCV infection: recipients of the transfusions or blood products before the donor screening program started in  ( subjects); intravenous drug users (), dialysis patients () and health-care workers (), and b) control group consisiting () volunteer blood donors who were randomly chosen. All participants of this study were examined clinically, they were tested on anti-HCV antibody with ELISA test third generation . Positive serum samples were tested on presence of HCV RNA by reverse transcription reaction and polymerase chain reaction made by Amplicor-Roche. All anti-HCV antibody positive patients were evaluated according to their epidemiological, clinical and biochemical tests. We have also collected general information from all examined as well as data about their risk factors. Statistical analysis was performed using descriptive statistical parameters (mean value-x, standard deviation-SD) and comparative methods . Statistical diff erences between two means were determined by Student's t-test. P<, was considered statistically significant.
Results
Prevalence of anti-HCV antibodies in subjects who have received blood transfusions before the HCV blood screening was introduced as routine method in Tuzla (at the end of ) was , (/); in intravenous drug users  (/); in the patients on long-term dialysis , (/), and in health care workers , (/). In Table  it is shown that  out of  patients (,) were anti-HCV positive. Prevalence of anti-HCV in the volunteer blood donors was , (/). There was statistically significant diff erence between frequency of anti-HCV antibodies found in test group (high risk subgroups) compared with its frequency in control group (P<,). In anti-HCV positive subjects, the largest part of infected was found in the risk group of hemodialysis patients (,) followed by blood transfusion recipients who received blood before screening for HCV was introduced (,), intravenous drug users (,), while it was the smallest in the health -care workers subgroup (,) , as is summarized in Table  . In the group of  anti-HCV positive subjects , (/) were identifi ed having HCV RNA, i.e., , of anti-HCV positive subjects had active HCV infection, while , (/) to had earlier HCV infection (Table ) . Compared between risk groups, highest percentage of HCV viremia was found in the group of hemodialysis patients -, (/), while the smallest percentage of HCV RNA was detected in the group of health care workers - (/), as it is shown in Table  antibodies live in Tuzla municipality (,). Mean age of anti-HCV positive subjects was ,±, years, while mean age of anti-HCV negative examinees was ,±, years. Th is diff erence is statistically signifi cant (P=,). Largest number of subjects (, or ,) was in the age group of - years, while  subjects (,) was in the age group of - years ( Table ) . Out of overall  anti-HCV positive examinees, , was in the age group of - years, while the smallest number (,) was in the age group of < years (Table ) . Th ere is statistically signifi cant diff erence in the presence of anti-HCV antibodies between subjects of various age groups (P=,). Th ere was no statistically signifi cant diff erence in distribution of anti-HCV antibodies related to the sex. More anti-HCV positive cases were registered among men (/) (p=,).
Screening of blood donors for HCV infection was introduced at Transfusiology institute UKC Tuzla at the end of  (second generation Elisa test)
. All  of examinees who received blood transfusion did it for therapeutic reasons.  of them (,) received  or more blood products. In the group of intravenous drug users, duration of intravenous drug abuse in HCV positive subjects was ,±, years, while in anti-HCV negative examinees ,±, years. Th is diff erence is statistically signifi cant and shows that duration of intravenous drug abuse is possible risk for HCV infection. Duration of hemodialysis, as possible risk factor for HCV infection, shows statistically signifi cant diff erence in the group of anti-HCV positive subjects (p <,), compared with duration of hemodialysis in the group of anti-HCV negative ones. Blood transfusion before , the other risk factor, was present in both risk groups. Largest number of subjects received more than two blood transfusions. Mean number of blood products given per patient was ,±, in the group of anti-HCV positive subjects, and ,±, in the group of anti-HCV negative ones (P=,). Duration of working life, as possible risk factor for HCV infection, was ,±, years in the group of anti-HCV positive subjects, compared with ,±, years in the group of anti-HCV negative ones. Th is diff erence is no statistically signifi cant (p=,). Mean number of accidental injuries, as possible risk factor for HCV infection, was , in the group of anti-HCV positive subjects, compared with , in the group of anti-HCV negative ones. This difference is statistically significant (p< ,).
Discussion
Studies of HCV infections that detect anti-HCV antibodies in diff erent risk groups are fi nding diff erent level of prevalence, higher than the prevalence in generalpopulation samples, depending on: risk for infection, use of different tests for detection of HCV infection, existing prevalence in general population, screening activities aimed at early detection of HCV infection, HCV infection prevention, etc. In our study, out of total number of  subject from various risk groups,  (,) were found to have anti-HCV antibodies. Statistically significant difference between numbers of anti-HCV antibodies-positive subjects in risk groups and control one was found (p<,). In the volunteer blood donors low prevalence of anti-HCV antibodies was found (,), because they are usually healthy young persons. Global data show that the prevalence of anti-HCV positive volunteer blood donors is probably higher in Japan and other Asian countries than in Europe and USA () . Obvious difference in presence of HCV infection between risk group and control group can be attributed to various risk factors for HCV infection transmission present in risk group. In risk group, HCV RNA was found in , of subjects. Th at confi rms that in risk groups, as well as in general population, in large percentage of cases chronic infection develops () . All HCV RNA positive patients are direct source of HCV infection, that fact should be kept in mind when working on HCV infection prevention. Th e fact that this study found that , times more infected persons in age group of - years than in other age groups corresponds with the data from other published studies, and it clearly shows that HCV infection is global health, social and economic problem that we will have to deal with in coming years (,) . Results of this research with registered prevalence of , (/) in the group of blood transfusion recipients who received blood for therapeutic purpose before HCV screening was introduced, are similar to the registered mean prevalence in comparable population in the USA. Th is similarity can be explained by the fact that the prevalence of positive tests for HCV infection is higher in Japan and the rest of Asia, than in Europe and USA (,) . In this research, high prevalence of anti-HCV antibodies was found in the group of hemodialysis patients, , (/), with , (/) patients in Hemodialysis center Tuzla and , (/) in Hemodialysis center Gračanica. Diff erent levels of prevalence of HCV infection in hemodialysis patients are the consequence of diff erent prevalence in general population of diff erent countries, but also by the dialysis process itself, as well as poor prevention of HCV infection spreading in some countries, or diff erent hemodialysis centers within same country. Detection, in this study, of HCV infection in , (/) of hemodialysis patients who did not receive blood transfusion, or received it after it was tested for HCV, suggests nosocomial spreading of HCV infection within hemodialysis department. Th is mechanism of spreading of HCV infection was proven many times (,) . Multiple blood transfusions before the blood screening for HCV was introduced, longer duration of intravenous drug abuse, longer duration of hemodialysis treatment, larger number of accidental injuries in health care workers are independent, statistically signifi cant risk factors in risk groups examined in this study. In all anti-HCV positive subjects, found in this study, further epidemiological and clinical workup are needed.
Conclusion
Results of this study confi rm that general screening for HCV infection is recommended in risk groups in order to detect HCV infection as early as possible, to prevent its occurrence and to treat it optimally. Screening should identify large number of infected patients who are without symptoms, but need long-term follow up in order to detect progression of disease and to recommend changes of lifestyle (i.e. avoidance of alcohol intake). Especially important is the fact that it is possible, using potentially eff ective drugs, to prevent occurrence of potentially grave consequences for life and health of infected person.
